SARS-CoV-2 infection-lung demage. Lung cancer and Covid-19 in the TERAVOLT clinical studys

Szondy Klára (1), Futácsi Balázs (2), Kis Sándor (3)
(1) Semmelweis Egyetem, Pulmonológiai Klinika, Budapest
(2) Semmelweis Egyetem, Radiológiai Klinika, Budapest
(3) Terézvárosi Egészségügyi Szolgálat, Tüdőgondozó, Budapest

Hopefully, towards the end of the Covid-19 pandemic, we intend to provide a brief overview of the infection, the pathogen, most effective treatment options, lung damage, and the results of TERAVOLT clinical trial, about patients with lung cancer, treated or not-treated, infected by SARS-CoV-2 virus. Tried to summarize the new diagnostic and therapy rules (bronchoscopy, chest x-ray, chest CT), and the potential new vaccinations. Authors provide a brief overview of the treatment of respiratory and cancer patients during infection, the continuation of inhalation drugs, immunotherapy and/or chemotherapy.